Ping Feng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ping Feng has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Hong Tang
Center of Infectious Diseases, West China Hospital, Sichuan University, Chengdu 610041, China
3 shared publications Liyu Chen
Center for Infectious Diseases West China Hospital, Sichuan University Chengdu China
2 shared publications- Binwu Ying
Department of Laboratory Medicine, Clinical Laboratory Medicine Research Center, West China Hospital Sichuan University, Sichuan Clinical Research Center for Laboratory Medicine Sichuan P. R. China
1 shared publication - Cong Liu
Center of Infectious Diseases, West China Hospital of Sichuan University, Chengdu 610041, Sichuan Province, People's Republic of China
1 shared publication - Daoyin Gong
Chengdu
1 shared publication En-Qiang Chen
Center of Infectious Diseases, West China Hospital of Sichuan University, Chengdu, China
1 shared publication
Latest Publications
- Open Access
- 8 November 2022
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 36 (12) , e24755
Metformin promotes smear conversion in tuberculosis‐diabetes comorbidity and construction of prediction models
Background: The comorbidity of tuberculosis (TB) and diabetes mellitus (DM) is a global health concern. Metformin is commonly used in DM but the potential effectiveness in comorbid patients is uncertain. This retrospective study aims to investigate the effect of metformin on TB‐DM comorbidity and construct prediction models.Methods: Patients diagnosed with TB‐DM in West China Hospital were retrospectively enrolled from Nov 2013 to Sep 2019. Electronic health records of patients were extracted. Two‐month smear conversion (2SC) was considered an outcome indicator of TB. Univariate and multivariate logistic regression (LR) were used to assess the role of metformin and other independent predictors. Meanwhile, prediction models were built by LR, elastic net regression, support vector machine, k‐nearest neighbors, and random forest.Results: A total of 927 individuals were recruited, among which 408 (44.01%) were metformin‐exposed patients. A higher 2SC rate was observed in the metformin users. Other impact factors such as smoking, glucose, and creatinine levels were also identified. Multivariable models were then constructed using filtered variables. The support vector machine model yields the highest AUC (0.808, 95% CI: 0.767–0.849) and specificity (83.24%). LR model outperformed others in terms of sensitivity (69.71%).Conclusion: This retrospective study of a large population from southwestern China provides strong clinical evidence for the positive effects of metformin in TB‐DM. Metformin is associated with a better therapeutic outcome and promising for the adjuvant therapy of TB‐DM. Furthermore, a combination of support vector machine and LR models is recommended to discriminate the patients with poor treatment outcomes.
- 8 November 2022
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 36 (12) , e24755
Open AccessMetformin promotes smear conversion in tuberculosis‐diabetes comorbidity and construction of prediction models
Background: The comorbidity of tuberculosis (TB) and diabetes mellitus (DM) is a global health concern. Metformin is commonly used in DM but the potential effectiveness in comorbid patients is uncertain. This retrospective study aims to investigate the effect of metformin on TB‐DM comorbidity and construct prediction models.Methods: Patients diagnosed with TB‐DM in West China Hospital were retrospectively enrolled from Nov 2013 to Sep 2019. Electronic health records of patients were extracted. Two‐month smear conversion (2SC) was considered an outcome indicator of TB. Univariate and multivariate logistic regression (LR) were used to assess the role of metformin and other independent predictors. Meanwhile, prediction models were built by LR, elastic net regression, support vector machine, k‐nearest neighbors, and random forest.Results: A total of 927 individuals were recruited, among which 408 (44.01%) were metformin‐exposed patients. A higher 2SC rate was observed in the metformin users. Other impact factors such as smoking, glucose, and creatinine levels were also identified. Multivariable models were then constructed using filtered variables. The support vector machine model yields the highest AUC (0.808, 95% CI: 0.767–0.849) and specificity (83.24%). LR model outperformed others in terms of sensitivity (69.71%).Conclusion: This retrospective study of a large population from southwestern China provides strong clinical evidence for the positive effects of metformin in TB‐DM. Metformin is associated with a better therapeutic outcome and promising for the adjuvant therapy of TB‐DM. Furthermore, a combination of support vector machine and LR models is recommended to discriminate the patients with poor treatment outcomes.
- Open Access
- 27 March 2020
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 39 (8) , 1593-1595
Brief report of the first cured 2019-nCoV pneumonia patient in West China Hospital
- 27 March 2020
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 39 (8) , 1593-1595
Open AccessBrief report of the first cured 2019-nCoV pneumonia patient in West China Hospital
- Open Access
- 1 March 2016
- Published by Wolters Kluwer Health in Medicine
- Vol. 95 (12) , e3103
Entecavir-Associated Thrombocytopenia in a Decompensated Cirrhotic Patient
Drug-associated thrombocytopenia is common and curable, but there were few reports about entecavir-associated thrombocytopenia.We report here a case of a 65-year-old female patient with decompensated cirrhosis. The patient developed a fatal thrombocytopenia while under entecavir treatment. After she received entecavir treatment for 4 days, the patient's platelet count dropped significantly to 1 × 10/L, accompanied with a manifestation of mild sclera bleeding. All diagnostic data suggested an entecavir-induced immunological thrombocytopenia. The patient eventually fully recovered after treated with daily intravenous immunoglobulin infusions.Actually, there were only a handful of reports that children or adults with chronic hepatitis B developed a thrombocytopenia due to nucleoside analogue medication. Timeliness of intravenous immunoglobulin infusion could stop the fatal bleeding for patients with entecavir-associated immunological thrombocytopenia. Hence, early diagnosis and treatment are recommended. Our case suggested that the platelet count should be monitored regularly in patients with decompensated cirrhosis with underline immunological disease while treated with ETV.
- 1 March 2016
- Published by Wolters Kluwer Health in Medicine
- Vol. 95 (12) , e3103
Open AccessEntecavir-Associated Thrombocytopenia in a Decompensated Cirrhotic Patient
Drug-associated thrombocytopenia is common and curable, but there were few reports about entecavir-associated thrombocytopenia.We report here a case of a 65-year-old female patient with decompensated cirrhosis. The patient developed a fatal thrombocytopenia while under entecavir treatment. After she received entecavir treatment for 4 days, the patient's platelet count dropped significantly to 1 × 10/L, accompanied with a manifestation of mild sclera bleeding. All diagnostic data suggested an entecavir-induced immunological thrombocytopenia. The patient eventually fully recovered after treated with daily intravenous immunoglobulin infusions.Actually, there were only a handful of reports that children or adults with chronic hepatitis B developed a thrombocytopenia due to nucleoside analogue medication. Timeliness of intravenous immunoglobulin infusion could stop the fatal bleeding for patients with entecavir-associated immunological thrombocytopenia. Hence, early diagnosis and treatment are recommended. Our case suggested that the platelet count should be monitored regularly in patients with decompensated cirrhosis with underline immunological disease while treated with ETV.
- Open Access
- 18 January 2012
- Published by Springer Nature in Virology Journal
- Vol. 9 (1) , 23
Study of the expression levels of Hepatocyte nuclear factor 4 alpha and 3 beta in patients with different outcome of HBV infection
Hepatocyte nuclear factors 4 alpha (HNF4α) and 3 beta (HNF3β) are members of a group of liver-enriched transcription factors (LETFs) that play important roles in regulating the replication of hepatitis B virus (HBV) and liver inflammation. However, the relationship of the level of HNF4α and HNF3β with the severity of HBV-infected liver diseases is unclear. In this study, liver tissue samples from different types of HBV patients were collected, and HNF4α and HNF3β expression were detected by immunohistochemistry. The expression of HNF4α was significant higher in patients with severe hepatitis B(SHB) than those with chronic hepatitis B(CHB) and liver cirrhosis(LC) (both P < 0.05), but similar between patients with CHB and LC (P > 0.05). And the expression of HNF3β was similar among patients with CHB, LC and SHB (P > 0.05 for all pairwise comparison). This suggests that the expression level of HNF4α was different in patients with different outcome of HBV infection, high expression level of HNF4α may correlate with occurrence of SHB
- 18 January 2012
- Published by Springer Nature in Virology Journal
- Vol. 9 (1) , 23
Open AccessStudy of the expression levels of Hepatocyte nuclear factor 4 alpha and 3 beta in patients with different outcome of HBV infection
Hepatocyte nuclear factors 4 alpha (HNF4α) and 3 beta (HNF3β) are members of a group of liver-enriched transcription factors (LETFs) that play important roles in regulating the replication of hepatitis B virus (HBV) and liver inflammation. However, the relationship of the level of HNF4α and HNF3β with the severity of HBV-infected liver diseases is unclear. In this study, liver tissue samples from different types of HBV patients were collected, and HNF4α and HNF3β expression were detected by immunohistochemistry. The expression of HNF4α was significant higher in patients with severe hepatitis B(SHB) than those with chronic hepatitis B(CHB) and liver cirrhosis(LC) (both P < 0.05), but similar between patients with CHB and LC (P > 0.05). And the expression of HNF3β was similar among patients with CHB, LC and SHB (P > 0.05 for all pairwise comparison). This suggests that the expression level of HNF4α was different in patients with different outcome of HBV infection, high expression level of HNF4α may correlate with occurrence of SHB
- 29 May 2010
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 55 (8) , 2373-2380
Nucleoside Analogue Can Improve the Long-Term Prognosis of Patients with Hepatitis B Virus Infection-Associated Acute on Chronic Liver Failure
The prognosis of patients with hepatitis B virus (HBV)-associated acute on chronic liver failure (ACLF) is extremely poor. This study was designed to evaluate the efficacy and safety of nucleoside analogue treatment of patients with HBV-associated ACLF. We used a retrospective review of eligible patients from April 2006 to December 2008. Eligible subjects received 0.5 mg entecavir daily until October 2009 (group A), 100 mg lamivudine daily until October 2009 (group B), or no nucleoside analogue (group C). The primary endpoints were three-month survival and the rate of recurrence of HBV-associated ACLF. The secondary endpoints were HBV DNA levels, liver function, the model of end-stage liver disease (MELD) score, and adverse events. A total of 104 consecutive patients were recruited, and 33, 34, and 37 patients were randomly allocated to groups A, B, and C, respectively. Although no significant difference in three-month survival was observed, levels of HBV DNA and rates of recurrence of HBV-associated ACLF were lower. Liver function and MELD score were not significantly improved despite significantly reduced HBV DNA levels. These data indicated that nucleoside analogue treatment did not improve the short-term prognosis of patients with HBV-associated ACLF although it was efficacious and safe in the management of HBV DNA levels. Intriguingly and importantly, continuous nucleoside analogue treatment can significantly reduce the rate of recurrence, which might be indicative of the further benefit of long-term survival.
- 29 May 2010
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 55 (8) , 2373-2380
Nucleoside Analogue Can Improve the Long-Term Prognosis of Patients with Hepatitis B Virus Infection-Associated Acute on Chronic Liver Failure
The prognosis of patients with hepatitis B virus (HBV)-associated acute on chronic liver failure (ACLF) is extremely poor. This study was designed to evaluate the efficacy and safety of nucleoside analogue treatment of patients with HBV-associated ACLF. We used a retrospective review of eligible patients from April 2006 to December 2008. Eligible subjects received 0.5 mg entecavir daily until October 2009 (group A), 100 mg lamivudine daily until October 2009 (group B), or no nucleoside analogue (group C). The primary endpoints were three-month survival and the rate of recurrence of HBV-associated ACLF. The secondary endpoints were HBV DNA levels, liver function, the model of end-stage liver disease (MELD) score, and adverse events. A total of 104 consecutive patients were recruited, and 33, 34, and 37 patients were randomly allocated to groups A, B, and C, respectively. Although no significant difference in three-month survival was observed, levels of HBV DNA and rates of recurrence of HBV-associated ACLF were lower. Liver function and MELD score were not significantly improved despite significantly reduced HBV DNA levels. These data indicated that nucleoside analogue treatment did not improve the short-term prognosis of patients with HBV-associated ACLF although it was efficacious and safe in the management of HBV DNA levels. Intriguingly and importantly, continuous nucleoside analogue treatment can significantly reduce the rate of recurrence, which might be indicative of the further benefit of long-term survival.